Late Onset Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Interventions
- Genetic: Blood DrawOther: Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test
- Registration Number
- NCT05010603
- Lead Sponsor
- Columbia University
- Brief Summary
The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.
- Detailed Description
The purpose of this study is to focus on the genetic influences on Alzheimer's disease (AD) risk. Specifically, the investigators hypothesize that one or more genes, other than the previously identified susceptibility gene apolipoprotein-E (APOE), or the 3 genes associated with early-onset familial AD, presenilin-1 (PS-1), presenilin-2 (PS-2) or B-amyloid precursor protein (APP), increase the risk of AD in families with multiple individuals affected with AD. The investigators propose to test this hypothesis by performing genetic linkage analysis in order to detect the chromosomal location of genes that may increase the risk of Alzheimer's disease. In addition, the investigators will study genes known to increase the risk of Alzheimer's disease and other related disorders such as early onset AD, Pick disease, corticobasal degeneration, progressive supranuclear palsy, and familial frontotemporal dementia with parkinsonism and Lewy Body Dementia.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 10000
- Established diagnosis of definite or probable AD or have a diagnosis of a related neurodegenerative disorder such as Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD) (will also recruit sporadic FTD and LBD) cases.
- a living sibling with probable or possible AD;
- a third living relative affected with AD (onset age 50 or older) or unaffected (60 or older);
- participants in the proband's generation with an identified companion serving as an informant;
- participants who have capacity to consent or participants lacking capacity to consent with a surrogate/proxy in place to provide consent.
- failure to identify an appropriate informant;
- uncertainty of the clinical diagnosis of Alzheimer's disease or other related disorder;
- discovery of additional diagnosis that could account for the clinical manifestations;
- unwillingness to participate;
- failure to identify a living sibling with AD or other related disorder (except in the cases of sporadic FTD and sporadic LBD);
- participants lacking the capacity to consent who do not have a surrogate or proxy or next of kin to provide consent.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Families with a history of Alzheimer's Disease Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test Families with two or more family members affected with Alzheimer's Disease Individuals with Dementia (Alzheimer's Disease) Blood Draw Individuals with dementia over the age of 65 Un-related, non-demented controls Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test Un-related, non-demented healthy controls over age 55 Families with a history of Alzheimer's Disease Blood Draw Families with two or more family members affected with Alzheimer's Disease Un-related, non-demented controls Blood Draw Un-related, non-demented healthy controls over age 55 Individuals with Dementia (Alzheimer's Disease) Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test Individuals with dementia over the age of 65
- Primary Outcome Measures
Name Time Method Total number of genes identified to be associated with the risk of AD 5 years Genetic Linkage Analysis to Identify Genes Associated with the risk of Alzheimer's Disease: Identification of genes by performing genetic linkage analysis, in order to detect the chromosomal location of genes that may increase the risk of Alzheimer's disease.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (11)
University of Pittsburgh
๐บ๐ธPittsburgh, Pennsylvania, United States
Rush University
๐บ๐ธAurora, Illinois, United States
Indiana University
๐บ๐ธBloomington, Indiana, United States
University of Miami
๐บ๐ธMiami, Florida, United States
North Carolina State University
๐บ๐ธRaleigh, North Carolina, United States
NCRAD at Indiana University
๐บ๐ธIndianapolis, Indiana, United States
Joanne Norton
๐บ๐ธSaint Louis, Missouri, United States
University of Texas Southwestern
๐บ๐ธDallas, Texas, United States
University of Washington
๐บ๐ธSeattle, Washington, United States
Columbia University Irving Medical Center
๐บ๐ธNew York, New York, United States
Mayo Clinic
๐บ๐ธRochester, Minnesota, United States